Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 天前评分90
正文 · 机器翻译
#ESMO26 🚀 RASolute 302 | III 期
👥 500 例 | 既往治疗过的 mPDAC
💊 Daraxonrasib（RAS(ON) 抑制剂）对比 化疗
📈 OS：13.2 对 6.7 个月（HR 0.40）
🧬 按 RAS 基因型的 OS 获益：
🔹 G12D：HR 0.49
🔹 G12V：HR 0.32
🔹 G12R：HR 0.61
📊 PFS：HR 0.55（BICR）
🎯 ORR：32% 对 11%
💡 新的 SOC！
@OncoAlert
2462 浏览 · 39 赞 · 21 转发 · 1 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org帖内回复
- Mohit Kasibhatla@MohitKasibhatla
@DraMartinezLago @OncoAlert @myESMO @GrupoTTD How does 20% better RR than chemo with only 1/3 of pts responding yield a doubling in mOS? Isn’t that an outsized benefit?
来源：Nieves Martinez Lago MD PhD · x.com